СПИСОК ЛИТЕРАТУРЫ

1. Аржанова О.Н., Кузнецова А.В. Лечение плацентарной недостаточности у беременных с антифосфолипидным синдромом и варикозной болезнью. //

Consilium medicum. - 2006. - N8, №6.

2. Афанасьева Н.В., Стрижаков А.Н. Исходы беременности и родов при фетоплацентарной недостаточности различной степени тяжести. Вопр. гинекол.,акушер., перинатал. 2004; 3(2): 7-13.

3. Бицадзе В.О. Патогенез, принципы диагностики и профилактики осложнений беременности, обусловленных тромбофилией. Дис. … докт.мед.наук.- М.2004.- 297с.

4 Геворкян М.А., Манухин И.Б. «Клинические лекции по гинекологической

эндокринологии». М. Гэотар-Медиа, 2006. – 320с.

5. Добрынина Л.А., Калашникова Л.А., Павлова Л.Н. Причины ишемического инсульта в молодом возрасте. Журнал неврологии и психиатрии им.С.С.Корсакова. 2011; 3: 4-8.

6. Калашникова Л.А. Цереброваскулярные нарушения при антифосфолипидном синдроме. Том 5. N1, 2011.

7. Калашникова Л.А. Неврология антифосфолипидного синдрома. М.: Медицина, 2003, 256 с.: ил.

8. Макаров О.В., Ткачев О.РН, Волкова Е.В. Преэклампсия и хроническая артериальная гипертензия. Клинические аспекты. - М.: «Гэотар-Медиа», 2010. - 136с.

9. Макаров И.О., Сидорова И.С. Современный взгляд на патогенез фетоплацентарной недостаточности// Материалы VII Росс форума Мать и дитя. М., 2005 - С.134

10. Макацария А.Д., Бицадзе В.О., Баймурадова С.М., Долгушина Н.В., Юдаева Л.С., Хизроева Д.Х., Акиньшина С.В. «Антифосфолипидный синдром – иммунная тромбофилия в акушерстве и гинекологии». М.,

«Триада-Х», 2007 – 456с.

11. Макацария А.Д., Белобородова Е.В., Бицадзе В.О., Баймурадова С.М.

«Гипергомоцистеинемия и осложнения беременности». М., Триада-Х, 2005. – 216с.

12. Макацария А.Д., Мищенко А.Л., Бицадзе В.О., Маров С.В. «Синдром диссеминированного внутрисосудистого свертывания крови в акушерской практике». М., Триада-Х, 2002.

13. Макацария А.Д., Бицадзе В.О., Акиньшина С.В. «Синдром системного воспалительного ответа в акушерстве».

14. Макацария А.Д., Бицадзе В.О., Акиньшина С.В. «Тромбозы и тромбоэмболии в ашерско-гинекологической клинике». М.: ООО

«Медицинское информационное агентство», 2007. – 1064с.

15. Макацария А.Д., Бицадзе В.О. «Тромбофилии и противотромботическая терапия в акушерской практике». М., Триада-Х, 2003. – 904с.

16. Макацария А.Д., Бицадзе В.О. «Тромбофилические состояния в акушерской практике». Научное издание. – М.: «Руссо», 2001. – 704с.

17. Мхеидзе Н.Э. Клиническое значение выявления генетической и приобретенной тромбофилии у беременных с преждевременной

отслойкой нормально расположенной плаценты в анамнезе. Дис. … канд.мед.наук.- М.2006.- 129с.

18. Насонов Е.Л. Ревматология. Национальное руководство. - М.: Гэотар- Медиа, 2008. -737с.

19. Насонов Е.Л. Антифосфолипидный синдром. Монография. - М.: Литтера, 2004.- 440 с.

20. Савельева Г.М., Шалина Р.И., Сичинава Л.Г., Панина О.Б., Курцер М.А.

«Акушерство. Учебник». М., Гэотар-Медиа, 2008. – 656с.

21. Серов В.Н. Плацентарная недостаточность.// Трудн Пац. 2005. Т3-№2.

С.18-19.

22. Стрижаков А.Н.. Игнатко И.В. «Потеря беременности». М. ООО

«Медицинское информационное агентство», 2007. – 224с.

23. Amengual O, Atsumi T, Khamashta MA, Tinahones F, Hughes GR. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol. 1997; 36: 964–968.

24. Arnout J, Meijer P, and Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia

(ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost 1999; 81(6):929–934.

25. Arulkumaran S. Clinical obstetrics and gynaecology. Inherited

thrombophilias. // Elsevier Company. – 2003. – 528p.

26. Asherson RA, Piette J-C, Cervera R. Primary, secondary, seronegative, catastrophic and other subsets of the antiphospholipid syndrome.

27. Asherson SA: New subsets of the antiphospholipid syndrome in 2006: 'PRE- APS' (probable APS) and microangipathic antiphospholipid syndrome ('MAPS'). Autoimmun. Rev. 6, 76–80 (2006).

28. Azem F, Many I, Yovel I, Amit A, Lessing JB, Kupferminc MJ. Increased rates of thrombophilia in women with repeated IVF failures. Human Reproduction Vol.19, N2, pp.368-370, 2004.

29. Atsumi T, Khamashta MA, Amengual O, Donohoe S, Mackie I, Ichikawa K, Koike T, Hughes GR. Binding of anticardiolipin antibodies to protein C via ß2- glycoprotein I (ß2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol. 1998; 112: 325–333.

30. Atsumi T, Khamashta MA, Haworth RS, Brooks G, Amengual O, Ichikawa K,

Koike T, Hughes GR. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum. 1998; 41: 800–

807.

31. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000; 43(9):1982–1993.

32. Atsumi T and Koike T. Antiprothrombin antibody: why do we need more assays? Lupus 2010; 19(4):436–439.

33. Audrain MA, El-Kouri D, Hamidou MA, et al. Value of autoantibodies to beta(2)-glycoprotein 1 in the diagnosis of antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41(5):550–553.

34. alen A.H. et al. Polycystic ovary syndrome. London and New York,

“Taylor&Francis”, 2005. – 256p.

35. Bancsi LF, van der Linden IK, Bertina RM. ß2-Glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost. 1992; 67: 649–653.

36. Bates SM. Pregnancy-associated venous thromboembolism:prevention and treatment. Seminars in Hematology, Vol 48, N4, October 2011, pp 271-284.

37. Bell WN, Alton HG. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test.

38. Bergrem A, Jacobsen EM, Skjeldestad FE, et al. (2010) The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis–a population-based case-control study. Thromb Res 125(5):e222–

e227.

39. Bick R.L. Disorders of thrombosis and hemostasis. Clinical and laboratory practice. // 3^rd edition by Lippincott Williams & Wilkins. – 2002. – 446p.

40. Bick R.L. Antiphospholipid syndrome in pregnancy. Hematology/Oncology clinics of North America. // by Saunders Company.- 2008. – 999-1203.

41. Blank M, Faden D, Tincani A, Kopolovic J, Goldberg I, Gilburd B, Allegri F, Balestrieri G, Valesini G, Shoenfeld Y. Immunization with anticardiolipin

cofactor (ß-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun. 1994; 7: 441–455.

42. Blank M, Krause I, Fridkin M et al.: Bacterial induction of autoantibodies to

^β2^{-glycoprotein-I accounts for the infectious etiology of antiphospholipid} syndrome. J. Clin. Invest. 109, 797–804 (2002).

43. Blickstein I. Obstetrics and gynecology clinics of North America.// - Thrombophilia and Women’s health. – Sept 2003. - Vol. 33, N 3.

44. Boffa M-C, Piette J-C. Papers and abstracts from the 9th International Symposium on Antiphospholipid Antibodies. Tours, France, September 12–16, 2000. J Autoimmun. 2000; 15: 81–A95.

45. Bose P, Black S, Kadyrov M, Weissenborn U, Neulen J, Regan L, Huppertz

B. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecolo 2005;192:23-30.

46. Bourne T., Condous G. Handbook of early pregnancy care. // Informa Healhcare Ltd. – 2006. – 158 p.

47. Bowie WEJ, Thompson JH, Pascuzzi CA, Owen GA. Thrombosis in systemic erythematosus despite circulating anticoagulants. J Clin Invest. 1963; 62: 416–

430.

48. Branch DW, Khamashta MA. Antiphospholipid syndrome.

2003 Jun; 101 (6):1333-44.

49. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004;114:409-14.

50. Brenner B, Aharon A. Sarig G. Antiphospholipid syndrome, heritable thrombophilia and early pregnancy loss. Textbook of Periconceptional Medicine. Edited by Nick S Macklon, Ian A Greer and Eric AP Steegers. CRC Press 2008; 349-356.

51. Brey RL, Stallworth CL, McGlasson DL, et al. Antiphospholipid antibodies and stroke in young women. Stroke 2002; 33(10):2396–2400.

52. Buckingham KL, Stone PR, Smith JF, Chamley LW. Antiphospholipid antibodies in serum and follicular fluid – is there a correlation with IVF implantation failure? Human Reproduction Vol.21, N3, pp.728-734, 2006.

53. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost. 1995; 73: 529–534.

54. Carmona F, Balasch J. Fetal and obstetric manifestations and infertility in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y (eds). The antiphospholipid Syndrome II: Autoimmune Thrombosis.

Amsterdam: Elsevier, 2002, 205-211.

55. Carp HJ, Shoenfeld Y. Anti-phospholipid antibodies and infertility. Clin Rev Allergy Immunol 2007;32:159-161.

56. Cervera R., Balasch J. Bidirectional effects on autoimmunity and

reproduction. Human Reproduction Update. May, 22, pp 1-8, 2008.

57. Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Seminars in Thrombosis and Hemostasis. Vol.38, N4/2012; 333-337.

58. Cockrell E, Espinosa R, McCrae. Annexin II: biology and relevance to the antiphospholipid syndrome. Lupus, October 1, 2008' 17(10):944-952.

59. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952;31:621.

60. Costa M, Colia D.

61. Crowther MA, Johnston M, Weitz J, Ginsberg JS. Free protein S deficiency

may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus. Thromb Haemost. 1996; 76: 689–691.

62. Day HM, Thiagarajan P, Ahn C, et al. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid

antibody tests. J Rheumatol 1998; 25(4):667–674

63. Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials. Br. J Obstetrics Gynaecol. 1989 Mar; 96 (3): 275-80.

64. Di Simone N, Luigi M, Marco D: Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies, a review of the literature. Ann. NY Acad. Sci. 1108, 505–514 (2007).

65. Dodd JM, Ashwood P, Flenady V, Jenkins-Manning S, Cincotte R. A survey of clinician and patient attitudes towards the use of progesterone for women at risk of preterm birth. Aust N Z J Obstetr Gynaecol. 2007 Apr; 47 (2): 106-9.

66. Donadini MP, Ageno W. Unusual site thrombosis. Seminars in Hematology, Vol 48, October 2011, pp 264-270.

67. Donadini MP, Dentani F, Ageno W. Splanchnic vein thrombosis: new risk factors and management. Thrombosis Research 129, Suppl 1 (2012) S93-S96.

68. Esmon NL, Safa O, Smirnov MD, Esmon CT. Antiphospholipid antibodies and the protein C pathway. J Autoimmun. 2000; 15: 221–225.

69. Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. Journal of

Thrombosis and Haemostasis, 2011; 9 (Suppl.1): 182-188.

70. Espinosa G, TassiesD, Reverter J-C. Hematological abnormalities in the antiphospholipid syndrome. 2002. Elsevier Science B.V. 259-276.

71. European Stroke Initiative Recommendations for Stroke Management – Update 2003. Cerebrovasc Dis 2003;16:311-337.

72. Favaloro EJ, Wong RCW. The antiphospholipid syndrome: diagnosis, pathogenesis, laboratory testing, and management. Seminars in Thrombosis

and Hemostasis. Vol.38, N4/2012; 299-304.

73. Favaloro EJ, Wheatland L et al. Internal quality control and external quality assurance in testing for antiphospholipidantibodies: part I – anticardiolipin and anti-b2-glycoprotein I antibodies. Seminars in thrombosis and hemostasis. Volume 38, Number 4/2012; 390-403.

74. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation.In: Spaet

TH, ed. Progress in Hemostasis and Thrombosis. Vol 1. New York, NY: Grune

& Stratton; 1972: 75–95.

75. Fiona Lyall, M. Belfort. Pre-eclampsia: etiology and clinical practice. // Cambridge University Press. – 2007. – 548p.

76. Fujimura Y, Matsumoto M, Yagi H. Thrombotic microangiopathy. Intern Med.

2010;49(1):7-15.

77. Furukawa S., Fujita T., Shimbakuro M. et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. // The Journal of Clinical Investigation. – 2004. – Vol. 114. - N.12. – P. 1752 – 1761.

78. Gabriel R. de Freitas, Bogousslavsky J. Risk factors of cerebral vein and sinus

thrombosis. Handbook on Cerebral Venous Thrombosis. Front Neurol Neurosci. Basel, Karger, 2008, vol 23, pp.23-54.

79. Galli M, Comfurius P, Maassen C, et al. (1990) Anticardiolipin antibodies

(ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335(8705):1544–1547.

80. Galli M. Interpretation and recommended testing for antiphospholipid antibodies. Seminars in Thrombosis and Hemostasis. Vol.38, N4/2012; 348- 352.

81. Gharavi AE, Vega-Ostertag M, Espinola RG et al.: Intrauterine fetal death in

mice caused by cytomegalovirus-derived peptide induced aPL antibodies.

Lupus 13, 17–23 (2004).

82. Gilham JC, Myers JE, Baker PN, Taggart MJ. TNF-α alters nitric oxide – and endothelium-derived hyperpolarizing factor-mediated vasodilatation in human

omental arteries. Hypertension in Pregnancy, 27:29-38, 2008.

83. Seminars in Thrombosis and Hemostasis. Vol.38, N4/2012; 328-332.

84. Ginsberg JS, Greer I, Hirsh J: Use of antithrombotic agents during pregnancy.

Chest 119(Suppl. 1), S122–S131 (2001).

85. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112:1644-1654.

86. Girardi G, Redecha P, Salmon J. Heparin prevents antiphospholipid antibody- induced fetal loss by inhibiting complement activation. Nat Med 2004; 10:1222.

87. Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of

unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 2005; 106:2921-2.

88. Groot PhG, Urbanus RT. The future of antiphospholipid antibody testing.

Seminars in thrombosis and hemostasis. Volume 38, Number 4/2012; 412-419.

89. Gushiken FC, Arnett FC, Thiagarajan P. Primary antiphospholipid antibody syndrome with mutations in the phospholipid binding domain of ß2- glycoprotein I. Am J Hematol. 2000; 65: 160–165.

90. Iorio A., Barnes C., Vedovati M-C. Thrombophilia and cerebral vein thrombosis. Handbook on Cerebral Venous Thrombosis. Front Neurol Neurosci. Basel, Karger, 2008, vol 23, pp.55-76.

91. Hameed A, Regan L. Acquired thrombophilia and recurrent early pregnancy

loss. In: Early Pregnancy, ed. Roy G. Farquharson and Mary D.Stephenson. Published by Cambridge University Press. 2010. 113-129.

92. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth Young CG, Loizou S, Hughes GR. Anticardiolipin antibodies: detection by radioimmunoassay and

association with thrombosis in systemic lupus erythematosus. Lancet. 1983; 2: 1211–1214.

93. Harris EN, Gharavi AE, Boey ML, et al. (1983) Anticardiolipin antibodies:

detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2(8361):1211–1214. Medline.

94. Harris EN, Hughes GRV, Gharavi AE. Antiphospholipid antibodies: an elderly statesman dons new garments. J Rheumatol. 1987; 14 (suppl 13): 208–213.

95. Hellan M, Kuhnel E, Speiser W, Lechner K, Eichinger S. Familial lupus anticoagulant. a case report and review of the literature. Blood Coagul Fibrinolysis. 1998; 9: 195–200.

96. Holers VM, Girardi G, Mo L, Gurthtidge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE et al. C3 activation is required for anti-phospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211-220.

97. Howard JA CARP. Recurrent pregnancy loss: causes, controversies and treatment. // Informa UK Ltd. – 2007. – 290p.

98. Hughes GR. The anticardiolipin syndrome. Clin Exp Rheumatol. 1985; 3: 285–286.

99. Hughes GR, Asherson RA, and Khamashta MA (1989) Antiphospholipid syndrome: linking many specialties. Ann Rheum Dis 48(5):355–356.

100. Hughes GR, Khamashta MA, Gharavi AE, Wilson WA. New Orleans 7th

International Symposium on Antiphospholipid Antibodies. Proceedings and abstracts. Lupus. 1996; 5: 343–558.

101. Hughes GRV, Khamashta MA. Seronegative antiphospholipid syndrome.

Ann Rheum Dis 2003;62:1127.

102. Kaul K, Erkan D, Artim-Esen B, Diz-Kucukkaya R, Inanc M, Lockshin MD: Warfarin alternatives for secondary thrombosis prophylaxis in antiphospholipid syndrome. Arthritis Rheum. 52, S595 (2005) (Abstract).

103. Kenet G, Aronis S, Berkun Y, Bonduel M. et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematicreview and meta-analysis. Seminars in thrombosis and

hemostasis. Volume 37, Number 7, 2012; 802-809.

104. Kershaw G, Suresh S, Orellana D, Nguy Y-M. Laboratory identification of lupus anticoagulants. Seminars in thrombosis and hemostasis. Volume 38, Number 4/2012; 375-384.

105. Khamashta MA. Systemic lupus erythrematosus and pregnancy. Best Pract Res Clin Rheumatol 2006; 20:685-94.

106. Krikun G, Lockwood CJ, Wu XX, Zhou XD, Guller S, Calandri C, Guha A, Nemerson Y, Rand JH. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta. 1994; 15: 601–612.

107. Kornberg A, Renaudineau Y, Blank M, Youinou P, Shoenfeld Y. Anti-ß2-

glycoprotein I antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells. Isr Med Assoc J. 2000; 2 (suppl 1): 27–31.

108. Kujovich J.L. Thrombophilia and pregnancy complications. // American Journal of Obstetrics and Gynecology. - 2004. - 191, 412-24.

109. Lakos G, Favaloro EJ, Harris EN, et al. International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein i testing: a report from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012; 64(1):1–10.

110. Lakos G. Interference in antiphospholipid antibody. Seminars in Thrombosis and Hemostasis. Vol.38, N4/2012; 353-359.

111. de Laat B, Pengo V, Pabinger I, et al. (2009) The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 7(11):1767–1773.

112. Laurell A, Nilsson I. Hypergammaglobulinemia, circulating anticoagulant and biologic false-positive Wassermann reaction. J Lab Clin Med. 1957; 49: 694–707.

113. Laskowska M, Laskowska K, Oleszczuk J. Interleukin-18 concentrations in

pregnancies complicated by preeclampsia with and without IUGR: a comparison with normotensive pregnant women with isolated IUGR and healthy pregnant women. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 1 (2011); 206-212.

114. Lefkou E, Hunt B. Pre-eclampsia. The Obstetric Hematology Manual, ed.

Sue Pavord and Beverly Hunt. 2010; 203-217.

115. Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood. 1991; 78: 2894–2899.

116. Leveno I., Kenneth J. Williams manual of obstetrics: pregnancy complications. 22-end edition. 2007. – 598p.

117. Levi M, Nieuwdorp M, Poll T, Stroes E. Metabolic Modulation of inflammation – induced activation of coagulation. Seminars in Thrombosis and

Hemostasis/Vol 34, Number 1; 2008:26-32.

118. Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Seminars in Thrombosis and Hemostasis. Vol.38, N4/2012; 339-347.

119. Lieby P, Poindron V, Roussi S. Et al. Pathogenic antiphospholipid antibody: an antigen-selected needle in haystack. Blood, September 15, 2004;

104(6):1711-1715.

120. de Lignieres B., Dennerstein L., Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas. 1995 Apr.; 21 (3): 251-

7.

121. Lin WS, Chen PC, Yang CD et al.: Some antiphospholipid antibodies ^{recognize conformational epitopes shared by β}2^{-glycoprotein I and the} homologous catalytic domains of several serine proteases. Arthritis Rheum. 56, 1638–1647 (2007).

122. Lockshin MD, Kim M, Laskin CA, et al. Lupus anticoagulant, but not anticardiolipin antibody, predicts adverse pregnancy outcome in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64(7):2311–2318.

123. Lockwood CJ, Huang SJ, Krikun G et al. Decidual hemostasis, inflammation

and angiogenesis in preeclampsia. Seminars in Thrombosis and Hemostasis/Vol 37, Number 2. 2011:158-163.

124. Lopez LR, Dier KJ, Lopez D, Merrill JT, and Fink CA. Anti-beta 2-

glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial

thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 2004; 121(1):142–149.

125. Luong T-H, Rand JH, Wu XX, Godbold JH, Gascon-Lema MG, Tuhrim S. Seasonal distribution of antiphospholipid antibodies. Stroke. 2001; 32: 1707–

1711.

126. Luoto R, Kharazami E, Whitley E et al. Systolic hypertension in pregnancy and cardiovascular mortality: a 44-year follow-up study. Hypertension in Pregnancy, 27:87-94, 2008.

127. Lyden TW, Vogt E, Ng AK, Johnson PM, Rote NS. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J

Reprod Immunol. 1992; 22: 1–14.

128. Lyle C.A., Bernard T.J., Goldenberg N.A. Childhood arterial ischemic stroke: a review of etiologies, antithrombotic treatments, prognostic factors, and priorities for future research. Seminars in thrombosis and hemostasis. Vol. 37. 7. 2011, p.786-793.

129. Macut D, Micic D, Suvajdzic N et al. Ovulation induction and early pregnancy loss in woman susceptible to autoimmune diseases: a possible interrelationship. Gynecol Endiocrinol 2000; 14: 153-7.

130. Manno M, Tomei F, Fasciani A, Costa M. Ovarian hyperstimulation syndrome: the best approaches for prevention and treatment. A mini-rewiev.

Curr Women's Health Rev 2007; 3:49-54.

131. Marai I, Carp HJA, Shai S, Shabo R, Fishman G, Shoenfeld Y. Autoantibody panel screening in recurrent miscarriages. Am J Reprod Immunol 2004; 51:235-240.

132. McCarty GA. Seronegative antibody syndrome (SNAPS) and snapping to it.

Vol 2. 2006.

133. McNeeley PA, Dlott JS, Furie RA, Jack RM, Ortel TL, Triplett DA, Victoria EJ, Linnik MD. ß2-Glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of ß2-glycoprotein I. Thromb Haemost. 2001; 86: 590–595.

134. Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A,

Khamashta MA, Balestrieri G, Tremoli E, Hess DC. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun. 2000; 15: 237–240.

135. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost 2006; 4(2):295–306.

136. Moore JE, Mohr CF. Biologically false positive serological tests for syphilis: type, incidence, and cause. J Am Med Assoc. 1952; 150: 467–473.

137. Moore JE, Lutz WB. Natural history of systemic lupus erythematosus: approach to its study through chronic biologic false positive reactors. J Chronic Dis. 1955; 1: 297–316.

138. oore HCF, Theriault RL. Commentary: ovarian function does not equal fertility does not equal babies. Oncologist 2007; 12: 1044-54.

138. Nisio M, Rutjes AWS, Ferrante N. Thrombophilia and outcomes of assisted reproduction technologies: a systemic review and meta-analysis. Blood. 2011; 118:2670-2678.

139. Ofosu FA. A review of the two major regulatory pathways for non- proproetary low-molecular-weight heparins. Thrombosis and Hemostasis;

107.2/2012.

140. Opatrny L, David M, Kahn SR, Shrier I, and Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006; 33(11):2214–2221.

141. Orchard E.A., Wilson N., Ormerod OJM. The management of cryptogenic stroke in pregnancy. Obstetric Medicine 2011; 4: 2-6.

142. Ostensen M, Khamashta M, Lockshin M et al. Anti-inflammatory and

immunosuppresive drugs and reproduction. Arthritis Res Ther 2006; 8:209.

143. Osturk MA, Haznedaroglu IC, Turgut M, and Goker H. Current debates in antiphospholipid syndrome: the acquired antibody-mediated thrombophilia. Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2):89-126.

144. Queenan John T. High-risk pregnancy. 2007. – 396p.

145. Paidas VJ, Han CS, Hossain N, Lockwood CJ. Inherited and acquired thrombophilia in obstetrics. In: Hemostasis and Thrombosis in Obstetrics and Gynecology, 1st edition. 2011. 67-110.

146. Palareti G, Schellong S. Isolated distal deep vein thrombosis: what we know and what we are doing. Journal of Thrombosis and Hemostasis, 10:11-19.

147. Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-

translational modification of beta 2 glycoprotein I. Journal of Thrombosis and Haemostasis, 2011; 9 (Suppl.1):274-282.

148. Pattison NS, Chamley LW, Birdsall M, Zanderig AM, Liddell HS, McDougall J: Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized control trial of

treatment. Obstet. Gynecol. 100, 408–413 (2002).

149. Pavord S, Myers B, Hunt B. Antiphospholipid syndrome. The Obstetric Hematology Manual, ed. Sue Pavord and Beverly Hunt. 2010; 131-139.

150. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost. 1996; 75: 721–724.

151. Pengo V. Antiphospholipid syndrome: interpretation of laboratory data.

Journal of Thrombosis and Haemostasis, 2011; 9 (Suppl.1): 402-420.

152. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What we have learned about antiphospholipid syndrome from patients and antiphospholipid

carrier cohorts. Seminars in Thrombosis and Hemostasis. Vol.38, N4/2012; 322-325.

153. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7(10):1737–1740.

154. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8(2):237–242.

155. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118(17):4714–4718.

156. Pham C, Shen Y-M. Antiphospholipid antibodies and malignancy.

Hematology/Oncology clinics of North America. 2008 Elsevier.

157. Pierangeli SS, Harris EN. In vivo models of thrombosis for the antiphospholipid syndrome. Lupus. 1996; 5: 451–455.

158. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GH, Harris EN: Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 99, 1997–2000

(1999).

158. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res. 2001; 88: 245–250.

159. Porter TF. Antiphospholipid antibodies and infertility. Clin Obstet Gynecol.

2001; 44: 29–35.

160. Powers RW, Roberts JM, Plymire DA, Pucci D et al. Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia. Type I versus Type 2 preeclampsia. Hypertension. Vol 60, Number 1, July 2012, 239-246.

161. Queenan John T., Hobbins John C., Spong C. Protocols for high-risk pregnancies. // 4th edition by Blackwell Publishing. – 2005. – 736p.

162. Quenby S, Mountfield S, Cartwright JE, Whitley GS, Chamley L, Vince G. Antiphospholipid antibodies prevent extravillous trophoblast differentiation. Fertil Steril 2005;83:691-698.

163. Raffaell De Caterina and peter Libby. Endothelial dysfunctions and vascular diseases. // Blackwell Publishing. – 2007. – 416p.

164. Rand JH, Wu XX, Guller S, Gil J, Guha A, Scher J, Lockwood CJ.

Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol. 1994; 171: 1566–1572.

165. Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, Harpel PC. Pregnancy loss in the antiphospholipid-antibody syndrome—a possible thrombogenic mechanism. N Engl J Med. 1997; 337: 154–160.

166. Rand JH, Wu XX, Andree HAM, Alexander Ross JB, Rosinova E, Gascon- Lema MG, Calandri C, Harpel PC. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood. 1998; 92: 1652–1660.

167. Rand JH. "Annexinopathies"—a new class of disease. N Engl J Med. 1999; 340: 1035–1036.

168. Rand JH, Wu XX, Giesen P. A possible solution to the paradox of the "lupus

anticoagulant": antiphospholipid antibodies accelerate thrombin generation by inhibiting annexin-V. Thromb Haemost. 1999; 82: 1376–1377.

169. Rand JH. The antiphospholipid syndrome.In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams’ Hematology. 6th ed. New

York, NY: McGraw-Hill; 2000: 1715–1733.

170. Rand JH, Wu X-X, Quinn AS et al. Human monoclonal antiphospholipid antibodiesdisrupt the annexin A5 anticoagulant crystal shield on phospholipidbilayers: evidence from atomic force microscopy and functional assay. Am.J.Pathol., September 1, 2003; 163(3): 1193-1200.

171. Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ:

Hydroxychloroquine directly reduces the binding of antiphospholipid ^antibody-β2^{-glycoprotein I complexes to phospholipid bilayers. Blood 112,} 1687–1695 (2008).

172. Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-ß2- glycoprotein I antibodies from autoantibody and immunized sources. J

Autoimmun. 2000; 15: 91–96.

173. Roberts JM, Escudero C. The placenta in preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 2; (2012), 72-83.

174. Rovensky K: Asherson syndrome – catastrophic antiphospholipid syndrome.

Autoimmun. Rev. 6, 61–63 (2006).

175. Roubey RA, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon ß2-glycoprotein I. J Clin Invest. 1992; 90: 1100–1104.

176. Ruiz-Irastorza, Khamashta MA. Stroke and antiphospholipid syndrome: the treatment debate. Rheumatology 2005; 44:971-974.

177. Ruffatti A, Calligaro A, Hoxha A, et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome.

Arthritis Care Res (Hoboken) 2010; 62(3):302–307.

178. Salmon JE, Girardi G, Holers VM: Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann. Rheum. Dis. 61(Suppl. 2), 46–50 (2002).

179. Sanmarco M, Soler C, Christides C, et al. Prevalence and clinical significance of IgG isotype anti-beta 2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med 1997; 129(5):499–506.

180. Seif AM, Hwang Y, Pierangeli S. Management of the antiphospholipid syndrome: new approaches. Int.J.Clin.Rheumatology. 2009; 4(5):533-549.

181. Shapiro SS, Thiagarajan P. Lupus anticoagulants. Prog Hemost Thromb.

1982; 6: 263–285.

182. Shu F, Sugimura M, Kanayama N, Kobayashi H, Kobayashi T, Terao T. Immunohistochemical study of annexin V expression in placentae of preeclampsia. Gynecol Obstet Invest. 2000; 49: 17–23.

183. Simmelink MJ, Horbach DA, Derksen RH, Meijers JC, Bevers EM, Willems GM, de Groot PG. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting

factors for catalytic phospholipid surfaces. Br J Haematol. 2001; 113: 621–629.

184. Soltesz P, Der H, Veres K, Laczik et al. Immunological features of primary anti-phospholipid syndrome in connrection with endothelial dysfunction. Rheumatology, November 1, 2008; 47(11): 1628-1634.

185. Stefano Raffaele Giannubilo and Andrea Luigi Tranquilli (2011). Fetal Thrombophilia, Thrombophilia, Prof. Prof. Andrea Tranquilli (Ed.).

186. Teixeira PG, Cabral ACV, Andrade SP. Placental Growth Factor (PIGF) is a surrogate marker in preeclamptic hypertension. Hypertension in Pregnancy, 27:65-73, 2008.

186. Tanne D, Levine SR, Brey RL et al. Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial. Neurology, October 28, 2003; 61(8): 1158-1159.

187. The European IVF-monitoring programme (EIM) for the European Society of Human Reproduction and Embriology (ESHRE). Assisted reproductive technology in Europe, 2002. Results generated from European registers by ESHRE. Hum Reprod 2006; 21:1680-97.

188. Tripodi A, Biasiolo A, Chantarangkul V, and Pengo V. Lupus anticoagulant

(LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem 2003; 49(10):1608–1614.

189. Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Seminars in thrombosis and hemostasis. Volume 38, Number 4/2012; 385-389.

190. Van JES, Eerenberg ES, Kamphuisen PW, Buller HR. How to prevent, treat, and overcome current clinical challenges of VTE. Journal of Thrombosis and

Haemostasis, 2011; 9 (Suppl.1): 265-274.

191. Vanderlelie J, Perkins AVA. Selenium and preeclampsia: a global perspective. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 1(2011); 213-224.

192. Visvanathan S, Geczy CL, Harmer JA, McNeil HP. Monocyte tissue factor induction by activation of ß2-glycoprotein-I-specific T lymphocytes is associated with thrombosis and fetal loss in patients with antiphospholipid antibodies. J Immunol. 2000;165:2258–2262.

193. Voges D, Berendes R, Burger A, Demange P, Baumeister W, Huber R. Three-dimensional structure of membrane-bound annexin V: a correlative electron microscopy-X-ray crystallography study. J Mol Biol. 1994;238:199–

213.

194. Wada H. Disseminated Intravascular Coagulation. Clin Chim Acta. 2004 June:344 (1-2):13-21.

195. Wang TH, Horng SG, Chang CL et al. Human chorionic gonadotrophin-

induced ovarian hyperstimulation syndrome is associated with up regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 2002;87:3300-8.

196. Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology, January 1, 2003; 2003(1):

497-519.

197. Warkentin TE. HIT paradigms and paradoxes. Journal of Thrombosis and Haemostasis, 2011; 9 (Suppl.1): 105-117.

198. Weiler H. Multiple receptor-mediated functions of activated protein C. Hamostaseologie 3/2011. 185-193.

199. Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. Seminars in Thrombosis and Hemostasis. Vol.38, N4/2012; 305- 317.

200. Wilson WA, Gharavi AE. Genetic risk factors for aPL syndrome. Lupus.

1996;5: 398–403.

201. Yasuda S, Tsutsumi A, Chiba H, Yanai H, Miyoshi Y, Takeuchi R, Horita T, Atsumi T, Ichikawa K, Matsuura E, Koike T. ß2-Glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis. 2000;152:337–346.